Drug intelligence / Profile preview

compound 22f

Development stage: Preclinical
Modality: Small Molecules

Overview

Compound 22f is a preclinical **small-molecule FLT3 inhibitor** described in a medicinal chemistry publication as a benzimidazole-indazole derivative developed for **acute myeloid leukemia**. It was optimized to inhibit mutant FLT3 kinase, including clinically relevant tyrosine kinase domain resistance mutations such as **D835Y** and **F691L**, and was reported to act as a **type 1 inhibitor** based on molecular docking. In the cited study, 22f showed subnanomolar to low-nanomolar biochemical potency against FLT3 and FLT3 D835Y and strong antiproliferative activity in FLT3-driven AML cell models, supporting its status as an early discovery-stage targeted antileukemic lead rather than a named clinical development candidate.

Other names: benzimidazole-indazole derivative 22f

Targets

FLT3 D835Y (Fms-like Tyrosine Kinase 3 Receptor D835Y Mutant)

Beyond the preview

Go deeper on compound 22f.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound 22f.

Explore the full profile